🇺🇸 Neridronate in United States

67 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 67

Most-reported reactions

1. Inflammation — 9 reports (13.43%)
2. Haemophagocytic Lymphohistiocytosis — 8 reports (11.94%)
3. Still^S Disease — 8 reports (11.94%)
4. Alanine Aminotransferase Increased — 6 reports (8.96%)
5. Aspartate Aminotransferase Increased — 6 reports (8.96%)
6. Blood Lactate Dehydrogenase Increased — 6 reports (8.96%)
7. Chemokine Increased — 6 reports (8.96%)
8. Faecal Calprotectin Increased — 6 reports (8.96%)
9. Interstitial Lung Disease — 6 reports (8.96%)
10. Off Label Use — 6 reports (8.96%)

Source database →

Frequently asked questions

Is Neridronate approved in United States?

Neridronate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Neridronate in United States?

Ente Ospedaliero Ospedali Galliera is the originator. The local marketing authorisation holder may differ — check the official source linked above.